RIT with y 90 -ibritumomab tiuxetan in follicular non-hodgkin lymphoma: Evaluation of recent outcomes in a single institution

Journal of Oncology

Volumn , Issue , 2012, Pages

  Andrade Campos, Marcio Miguel ^a   Montes Limón, Anel E ^a   Grasa, Jose María ^a   Lievano, Paola ^a   Baringo, Teresa ^a   Giraldo, Pilar ^a,b,c  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IBRITUMOMAB TIUXETAN; YTTRIUM 90;

ADULT; AGED; BONE MARROW TOXICITY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CLINICAL PROTOCOL; CONTROLLED STUDY; DATA BASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; HUMAN TISSUE; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OUTCOME ASSESSMENT; PROSTATE CANCER; RADIOIMMUNOTHERAPY; REVIEW; TREATMENT RESPONSE;

EID: 84867836481     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/412742     Document Type: Review

References (15)

1. Hiddemann W., Kneba M., Dreyling M., Schmitz N., Lengfelder E., Schmits R., Reiser M., Metzner B., Harder H., Hegewisch-Becker S., Fischer T., Kropff M., Reis H. E., Freund M., Wörmann B., Fuchs R., Planker M., Schimke J., Eimermacher H., Trümper L., Aldaoud A., Parwaresch R., Unterhalt M., Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005 106 12 3725 3732 2-s2.0-28544435078 10.1182/blood-2005-01-0016 (Pubitemid 41742196)
2. Press O. W., Radiolabeled antibody therapy of B-cell lymphomas. Seminars in Oncology 1999 26 5 58 65 2-s2.0-0032719113 (Pubitemid 29523412)
3. Illidge T., Morschhauser F., Radioimmunotherapy in follicular lymphoma. Best Practice & Research 2011 24 2 279 293 2-s2.0-79958277626 10.1016/j.beha.2011.03.005
4. Witzig T. E., Gordon L. I., Cabanillas F., Czuczman M. S., Emmanouilides C., Joyce R., Pohlman B. L., Bartlett N. L., Wiseman G. A., Padre N., Grillo-López A. J., Multani P., White C. A., Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology 2002 20 10 2453 2463 2-s2.0-0037093241 10.1200/JCO.2002.11.076 (Pubitemid 34525730)
5. Morschhauser F., Radford J., van Hoof A., Vitolo U., Soubeyran P., Tilly H., Huijgens P. C., Kolstad A., D'Amore F., Diaz M. G., Petrini M., Sebban C., Zinzani P. L., Van Oers M. H. J., Van Putten W., Bischof-Delaloye A., Rohatiner A., Salles G., Kuhlmann J., Hagenbeek A., Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. Journal of Clinical Oncology 2008 26 32 5156 5164 2-s2.0-55949118446 10.1200/JCO.2008.17.2015
6. Morschhauser F., Dreyling M., Rohatiner A., Hagemeister F., Bischof Delaloye A., Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence. The Oncologist 2009 14 supplement 2 17 29 2-s2.0-75349085058
7. 90Y-ibritumomab tiuxetan as frist-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin's lymphoma. Cancer Management and Research 2009 2 131 136
8. Hainsworth J., Spigel D., Markus T., Shipley D., Thompson D., Rotman R., Dannaher C., Greco F. A., Rituximab plus short-duration chemotherapy followed by Yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-hodgkin lymphoma: a phase II trial of the Sarah Cannon oncology research consortium. Clinical Lymphoma & Myeloma 2009 9 3 223 228 2-s2.0-69149103542 10.3816/CLM.2009.n.044
9. + B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004 103 12 4429 4431 2-s2.0-2942595713 10.1182/blood-2003-11-3883 (Pubitemid 38745967)
10. Zinzani P. L., Gandolfi L., Stefoni V., Fanti S., Fina M., Pellegrini C., Montini G. C., Derenzini E., Broccoli A., Argnani L., Pileri S., Baccarani M., Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. Clinical Lymphoma, Myeloma and Leukemia 2010 10 4 258 261 2-s2.0-77957092383 10.3816/CLML.2010.n.054
11. Illidge T. M., Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date? Journal of Clinical Oncology 2010 28 18 2944 2946 2-s2.0-77954619428 10.1200/JCO.2009.26.8748
12. + B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology 1999 17 12 3793 3803 2-s2.0-0032761164
13. Witzig T. E., Molina A., Gordon L. I., Emmanouilides C., Schilder R. J., Flinn I. W., Darif M., Macklis R., Vo K., Wiseman G. A., Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007 109 9 1804 1810 2-s2.0-34247561116 10.1002/cncr.22617 (Pubitemid 46668544)
14. Witzig T. E., Flinn I. W., Gordon L. I., Emmanouilides C., Czuczman M. S., Saleh M. N., Cripe L., Wiseman G., Olejnik T., Multani P. S., White C. A., Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. Journal of Clinical Oncology 2002 20 15 3262 3269 2-s2.0-0036682214 10.1200/JCO.2002.11.017 (Pubitemid 34831524)
15. Weigert O., Illidge T., Hiddemann W., Dreyling M., Recommendations for the use of Yttrium-90 ibritumomab tiuxetan in malignant lymphoma. Cancer 2006 107 4 686 695 2-s2.0-33747260159 10.1002/cncr.22066